INFI
Price:
$0.008
Market Cap:
$726.09K
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, ...[Read more]
Industry
Biotechnology
IPO Date
2000-07-28
Stock Exchange
NASDAQ
Ticker
INFI
According to Infinity Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -36669911.00. This represents a change of -329.40% compared to the average of 15.99M of the last 4 quarters.
The mean historical Enterprise Value of Infinity Pharmaceuticals, Inc. over the last ten years is 173.69M. The current -36669911.00 Enterprise Value has changed -2211.23% with respect to the historical average. Over the past ten years (40 quarters), INFI's Enterprise Value was at its highest in in the September 2013 quarter at 784.08M. The Enterprise Value was at its lowest in in the June 2016 quarter at -36797707.54.
Average
173.69M
Median
93.67M
Minimum
12.06M
Maximum
607.01M
Discovering the peaks and valleys of Infinity Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 513.84%
Maximum Annual Enterprise Value = 607.01M
Minimum Annual Increase = -94.44%
Minimum Annual Enterprise Value = 12.06M
Year | Enterprise Value | Change |
---|---|---|
2022 | 12.58M | -88.89% |
2021 | 113.30M | -6.97% |
2020 | 121.79M | 254.35% |
2019 | 34.37M | 104.96% |
2018 | 16.77M | -77.35% |
2017 | 74.03M | 513.84% |
2016 | 12.06M | -94.44% |
2015 | 216.73M | -58.97% |
2014 | 528.26M | -12.97% |
2013 | 607.01M | -35.02% |
The current Enterprise Value of Infinity Pharmaceuticals, Inc. (INFI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
82.56M
5-year avg
59.76M
10-year avg
173.69M
Infinity Pharmaceuticals, Inc.’s Enterprise Value is less than NextCure, Inc. (11.01M), less than Chimerix, Inc. (57.94M), less than Eledon Pharmaceuticals, Inc. (233.30M), less than Kiromic BioPharma, Inc. (13.48M), less than Neoleukin Therapeutics, Inc. (-6333315.00), less than CytomX Therapeutics, Inc. (39.67M), less than Assembly Biosciences, Inc. (68.59M), less than Instil Bio, Inc. (165.40M), less than Nuvation Bio Inc. (923.54M), less than Generation Bio Co. (163.63M), less than Kronos Bio, Inc. (5.32M), less than Erasca, Inc. (747.42M), less than C4 Therapeutics, Inc. (307.45M), less than Edgewise Therapeutics, Inc. (3.01B), less than Lyra Therapeutics, Inc. (23.90M), less than Trevi Therapeutics, Inc. (208.74M), less than SQZ Biotechnologies Company (24.11M), less than Protara Therapeutics, Inc. (2.28M), less than TRACON Pharmaceuticals, Inc. (-6162490.00), less than Aditxt, Inc. (14.61M), less than NeuroBo Pharmaceuticals, Inc. (-1095056.00), less than Dermata Therapeutics, Inc. (-3823196.00), less than Unicycive Therapeutics, Inc. (23.47M), less than Revelation Biosciences, Inc. (-3300245.00),
Company | Enterprise Value | Market cap |
---|---|---|
11.01M | $33.33M | |
57.94M | $80.94M | |
233.30M | $239.55M | |
13.48M | $1.69M | |
-6333315.00 | $8.20M | |
39.67M | $69.65M | |
68.59M | $95.60M | |
165.40M | $170.65M | |
923.54M | $942.39M | |
163.63M | $91.51M | |
5.32M | $54.49M | |
747.42M | $763.36M | |
307.45M | $300.00M | |
3.01B | $3.05B | |
23.90M | $12.37M | |
208.74M | $223.68M | |
24.11M | $12.83M | |
2.28M | $49.31M | |
-6162490.00 | $107.51K | |
14.61M | $4.82M | |
-1095056.00 | $20.42M | |
-3823196.00 | $2.32M | |
23.47M | $55.01M | |
-3300245.00 | $3.24M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Infinity Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Infinity Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Infinity Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Infinity Pharmaceuticals, Inc. (INFI)?
What is the 3-year average Enterprise Value for Infinity Pharmaceuticals, Inc. (INFI)?
What is the 5-year average Enterprise Value for Infinity Pharmaceuticals, Inc. (INFI)?
How does the current Enterprise Value for Infinity Pharmaceuticals, Inc. (INFI) compare to its historical average?